Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Stay up-to-date with the latest and best audio content from CBC Listen delivered to your inbox every two weeks.